Lots of interesting abstracts and cases were submitted for TCTAP 2022. Below are the accepted ones after a thorough review by our official reviewers. Don’t miss the opportunity to expand your knowledge and interact with authors as well as virtual participants by sharing your opinion in the comment section!
TCTAP A-037
Prognostic Impact of CHA2DS2-VASc-HS Score on Midterm Clinical Outcomes after Elective PCI for Chronic Coronary Syndrome: A Single-center Retrospective Study
By Tomoaki Ukaji, Tetsuya Ishikawa, Kota Yamada, Yukiko Mizutani, Hidehiko Nakamura, Itaru Hisauchi, Yuji Itabashi, Shiro Nakahara, Sayuki Kobayashi, Isao Taguchi
Presenter
Tomoaki Ukaji
Authors
Tomoaki Ukaji1, Tetsuya Ishikawa2, Kota Yamada1, Yukiko Mizutani1, Hidehiko Nakamura1, Itaru Hisauchi1, Yuji Itabashi1, Shiro Nakahara1, Sayuki Kobayashi1, Isao Taguchi1
Affiliation
Dokkyo Medical University, Japan1, Dokkyo Medical University Saitama Medical Center, Japan2
View Study Report
TCTAP A-037
Complex and Higher Risk Procedures for Indicated Patients (CHIP)
Prognostic Impact of CHA2DS2-VASc-HS Score on Midterm Clinical Outcomes after Elective PCI for Chronic Coronary Syndrome: A Single-center Retrospective Study
Tomoaki Ukaji1, Tetsuya Ishikawa2, Kota Yamada1, Yukiko Mizutani1, Hidehiko Nakamura1, Itaru Hisauchi1, Yuji Itabashi1, Shiro Nakahara1, Sayuki Kobayashi1, Isao Taguchi1
Dokkyo Medical University, Japan1, Dokkyo Medical University Saitama Medical Center, Japan2
Background
Weretrospectively examined the association of CHA2DS2-VASc-HS score on midtermclinical outcomes after elective PCI for chronic coronary syndrome (CCS),because the prognostic impact of CHA2DS2-VASc-HS score on the patients with CCSwas not fully understood in the present drug-eluting stent (DES) era.
Methods
Forthis purpose, consecutive 588 denovo coronary stenosis in 376 patients with CCSsuccessfully revascularized during from 2017 January to 2019 December wasdivided into two groups with CHA2DS2-VASc-HS score of 6 points: low (L: n=483)and high (H: n=105) groups. The primary clinical endpoint was the incidence oftarget lesion failure (TLF) comprising of cardiac death, non-fatal myocardialinfarction, and any target vessel revascularization.
Results
Thefrequency of TLF in H group (21.0% with the mean observational interval of652±468 days) was significantly higher than that in L group (p<0.001).Cumulated TLF-free ratio of H group was significantly lower than that in Lgroup (p<0.001, by log-rank test). Multivariate Cox hazard proportionalanalysis showed that CHA2DS2-VASc-HS score <=6 was the single significantpredictor of TLF among 29 variables (Hazard ratio: 2.26, 95%CI: 1.30-3.93,p=0.004).
Conclusion
Thus,the present retrospective single center analysis showed the significantprognostic impact of CHA2DS2-VASc-HS score on the incidence of midterm clinicaloutcomes after elective PCI for patients with CCS.